The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Aiding IMAX’s lofty box office goals is the Chinese title “Ne Zha 2,” which has already garnered $1.6 billion globally, including IMAX screenings.

It extends a tumultuous period for UnitedHealth marked by the killing of a top executive, a costly cyberattack against its subsidiary and high medical costs.